Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6.14M
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
1.89M
-
Shares change
-
+646K
-
Total reported value, excl. options
-
$5.11M
-
Value change
-
+$1.7M
-
Put/Call ratio
-
10.95
-
Number of buys
-
16
-
Number of sells
-
-7
-
Price
-
$2.70
Significant Holders of QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) as of Q1 2021
39 filings reported holding QLGN - QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share as of Q1 2021.
QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.89M shares
of 6.14M outstanding shares and own 30.85% of the company stock.
Largest 10 shareholders include BlackRock Inc. (318K shares), VANGUARD GROUP INC (301K shares), CITADEL ADVISORS LLC (226K shares), GEODE CAPITAL MANAGEMENT, LLC (153K shares), COMMONWEALTH EQUITY SERVICES, LLC (124K shares), PRICE T ROWE ASSOCIATES INC /MD/ (108K shares), QS Investors, LLC (82K shares), HighMark Wealth Management LLC (80.1K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (58.5K shares), and HATTON CONSULTING, INC. (57.2K shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.